FHC has adapted its patient-specific microTargeting stereotactic platform featuring patented STarFix™ technology, which has been used since 2001, to accurately place over 7,500 DBS leads to address the needs of the drug-resistant epilepsy market. FHC now provides a full suite of products that provide solutions for placing sEEG depth electrodes and tools from major vendors, and treatment using laser ablation or brain-responsive neurostimulation.

*microTargeting™, STarFix™, and WayPoint™ are trademarks of FHC, Inc.*
COMPLETE solutions for epilepsy localization and treatment surgeries:
pre-operative, intra-operative, and post-operative

Highly efficient work-flow significantly reduces OR time

“Made for epilepsy” patient-specific STarFix stereotactic platforms

Simultaneous access to all trajectories

Unique epilepsy specific functions in WayPoint Navigator

More than 220 surgeries have been completed by over 25 surgeons

FHC provides COMPLETE solutions for performing epilepsy surgeries that include

- Patient-specific stereotactic platforms
- Unrestricted positioning of the anchors, selection of entry points and trajectory orientations
- WayPoint Navigator planning and analysis software
- All required guides and tools and 24 hour technical support, worldwide

FHC solutions support

- SEEG with Integra depth electrodes and FHC insertion tubes
- SEEG with AdTech depth electrodes, bolts and tools
- SEEG with PMT® depth electrodes, bolts and tools
- SEEG with Dixi depth electrodes, bolts and tools
- Visualase laser ablation system
- Monteris laser ablation system
- NeuroPace RNS® system
- Adaptable for the devices of the future
Patient Specific microTargeting Platforms

FHC now offers versions of our field-proven microTargeting Platform featuring STarFix technology that support placement of the SEEG depth electrodes, laser ablation systems and brain-responsive neurostimulation leads. All epilepsy solutions offer the same benefits as the microTargeting Platform for DBS:

- WayPoint anchors/fiducials placed up to 28 days before surgery
- Arrives pre-configured, ready for use
- Simple and quick attachment to WayPoint anchors – no registration required in OR
- Simultaneous availability of all trajectories
- Small and lightweight, designed for a large range of skull sizes, including pediatric use

“I frequently use the microTargeting Multi-Oblique Platform for my SEEG cases. By eliminating the need to reposition a stereotactic frame for each electrode implant, the platform has significantly reduced the average duration of these procedures.”

— Dr. Joshua Aronson, Dartmouth-Hitchcock Medical Center

Localization + Treatment = Additional Efficiencies

WayPoint anchors placed to create and attach the SEEG platform can be left in place and reused to create a second platform to place laser ablation system or brain-responsive neurostimulation leads. In addition WayPoint Navigator 4.5 allows SEEG leads AND monitoring results to be visualized when planning treatment trajectories.

The microTargeting Multi-Oblique Platform allows placement of multiple depth electrodes at any location and orientation. Each small trajectory hub is placed at a surgeon specified distance from the skull. The distance from each trajectory hub to target is provided, along with skull thickness, to set implant distance. Simultaneous access to all trajectories allows work flows that would not be possible with standard stereotactic frames or robots. Guides and tools are provided to support all major vendors, and other tool guides can be created upon request.

For treatment, a single trajectory microTargeting Multi-Oblique Platform can be used to place the skull bolt for the Visualase® Ablation system or the lead for the NeuroPace RNS® system. FHC also offers a separate option using a unilateral DBS platform with FHC NeuroBlate adapter to place the Monteris mini-bolt for the NeuroBlate® Ablation system.
Unique Epilepsy features of WayPoint Navigator 4.5

FHC WayPoint Navigator software for DBS procedures has been enhanced with a number of unique features designed specifically for epilepsy surgical procedures.

- Planning and creation of FHC microTargeting epilepsy platforms
- Detection of collisions between electrodes
- Automatic measurement of skull thickness and incidence angle
- Anatomical atlas with epilepsy and user definable targets
- Automatic selection of optimal vendor-specific SEEG electrodes for each trajectory
- Visualization of SEEG electrodes in 2D and 3D views
- Record monitoring results and view activity at each contact over time

WayPoint Navigator now allows users to trace contours for creating volumetric representations of brain areas to be resected or ablated.
**microTargeting neuroCase**

FHC’s neuroCase provides on-site per case support (including a product support specialist) and pay-per-use case support (including equipment and a specialist).

Schedule your next surgery with the confidence of knowing that costs, supply, and procedural support issues are under control. We supply state-of-the-art neuromodulation systems, precise positioning devices, premium microelectrodes and other supplies, as well as our experienced technical support specialists—on a per case, pay-per-use charge specifically tailored to your requirements.

neuroCase packages for epilepsy feature your choice of:
- Product support specialists to handle installation, set-up and operation
- All required guides and tools, including extra consumables as needed for case backup
- microTargeting Platforms – no capital stereotactic solution ideal from new clinical sites or sites looking to maximize OR efficiency
- “Enhanced for Epilepsy” WayPoint Navigator – Pay-per-use or ownership options available

FHC provides comprehensive 24-hour technical support for all of our clinical and research products, worldwide.
FHC, Inc. has served the neuroscience community for 50 years in its mission to advance cranial microTargeting worldwide. With a guiding principle of innovation through collaboration, FHC designs, manufactures, and internationally markets products that provide pioneering solutions for neuroscientists, neurologists, and neurosurgeons. FHC is headquartered in Bowdoin, Maine and operates globally with locations in Pennsylvania, South America and Europe.

*Dr. Benabid’s visit to dedicate our new Bowdoin, Maine facilities in 2005.*